The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Open accessAbstract
BACKGROUND: Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-negative breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until disease progression or an unacceptable level of toxic effects occurred. Stratification factors were the receipt or nonreceipt of neoadjuvant or adjuvant taxane therapy, the presence or absence of liver metastases at baseline, and programmed death ligand 1 (PD-L1) expression at baseline (positive vs. negative). The two primary end points were progression-free survival (in the intention-to-treat population and PD-L1-positive subgroup) and overall survival (tested in the intention-to-treat population; if the finding was significant, then it would be tested in the PD-L1-positive subgroup). RESULTS: Each group included 451 patients (median follow-up, 12.9 months). In the intention-to-treat analysis, the median progression-free survival was 7.2 months with atezolizumab plus nab-paclitaxel, as compared with 5.5 months with placebo plus nab-paclitaxel (hazard ratio for progression or death, 0.80; 95% confidence interval [CI], 0.69 to 0.92; P=0.002); among patients with PD-L1-positive tumors, the median progression-free survival was 7.5 months and 5.0 months, respectively (hazard ratio, 0.62; 95% CI, 0.49 to 0.78; P<0.001). In the intention-to-treat analysis, the median overall survival was 21.3 months with atezolizumab plus nab-paclitaxel and 17.6 months with placebo plus nab-paclitaxel (hazard ratio for death, 0.84; 95% CI, 0.69 to 1.02; P=0.08); among patients with PD-L1-positive tumors, the median overall survival was 25.0 months and 15.5 months, respectively (hazard ratio, 0.62; 95% CI, 0.45 to 0.86). No new adverse effects were identified. Adverse events that led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel. CONCLUSIONS: Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, PD-L1 status by SP142 is the companion test for the use of atezolizumab in combination with a taxane for first-line therapy in triple-negative ABC, with a cut-off of 1% positive staining on immune cells.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an analysis was conducted and presented, and showed an OS of 25 months versus 15.1 months favouring the atezolizumab arm.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PD-L1 positive group, atezolizumab provided a PFS benefit of 7.5 versus 5 months with a HR of 0.62 (95% CI 0.49-0.78, P < 0.001).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“In the ITT population, atezolizumab provided a benefit in PFS of 7.2 versus 5.5 months with a HR of 0.8 (95% CI 0.69-0.92, P = 0.002).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“In the ITT population, there was no significant benefit in OS with the addition of atezolizumab; median OS was 21.3 months versus 17.6 months (HR 0.84; 95% CI 0.69-1.02, P = 0.08).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
In the citing paper
“to date, atezolizumab, in combination with chemotherapy, has been approved by the FDA for the treatment of squamous and nonsquamous NSCLC, small cell lung cancer, and PD-L1-positive triple-negative breast cancer (66)(67)(68)(69).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G. D., Goldstein, N. S., Hayes, M. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,217
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F. M., Poortmans, P. M., Rutgers, E. J. T., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,660
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Eenoo, F. V., Rouas, G., Francis, P. A., Crown, J. P., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,658
Self-citationPD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,420
Flagged first, then by citations
Research works printed but not linked: 1
- Adams S Diamond JR Hamilton E et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol (in press).
Cited by
Sorted by citations
Items 501–600 of 1,010
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Pang, L., Chen, G., Xu, J. Y., Jia, Y., Chai, J., Huang, R., Li, A., Ge, H., Yu, S., & Cheng, H. (2022) · Cancers · doi:10.3390/cancers14235727 · Cited by 93
Role of Immunotherapy in Breast Cancer
Jacob, S. L., Huppert, L. A., & Rugo, H. S. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00483 · Cited by 81
Self-citationCell cycle dysregulation in cancer
Glaviano, A., Singh, S. K., Lee, E. H. C., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O’Connor, M. J., Koff, A., Singh, G., et al. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100030 · Cited by 98
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Ponde, N. F., Aftimos, P. G., & Piccart, M. J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0633-6 · Cited by 80
Advances in Targeted Therapies for Triple-Negative Breast Cancer
McCann, K. E., Hurvitz, S. A., & McAndrew, N. P. (2019) · Drugs · doi:10.1007/s40265-019-01155-4 · Cited by 81
Hamid, O., Molinero, L. L., Bolen, C. R., Sosman, J. A., Muñoz‐Couselo, E., Kluger, H. M., McDermott, D. F., Powderly, J. D., Sarkar, I., Ballinger, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3488 · Cited by 82
Self-citationNgamcherdtrakul, W., & Yantasee, W. (2019) · Translational research · doi:10.1016/j.trsl.2019.08.005 · Cited by 81
Breast cancer stem cell antigens as targets for immunotherapy
Quaglino, E., Conti, L., & Cavallo, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101386 · Cited by 84
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 82
Borel, C., Jung, A. C., & Burgy, M. (2020) · Cancers · doi:10.3390/cancers12092691 · Cited by 78
Gibson, J. T., Orlandella, R. M., Turbitt, W. J., Behring, M. P., Manne, U., Sorge, R. E., & Norian, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590794 · Cited by 81
Li, J., Wang, S., Wang, N., Zheng, Y., Yang, B., Wang, X., Zhang, J., Pan, B., & Wang, Z. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00775-2 · Cited by 82
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85
Luo, Z., Mei, J., Wang, X., Wang, R., He, Z., Geffen, Y., Sun, X., Zhang, X., Xu, J., Wan, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114697 · Cited by 85
Berckelaer, C. V., Rypens, C., van Dam, P. A., Pouillon, L., Parizel, P. M., Schats, K., Kockx, M. M., Tjalma, W. A. A., Vermeulen, P. B., Laere, S. V., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1108-1 · Cited by 80
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 78
Current status and limitations of immunotherapy for breast cancer
Tokumaru, Y., Joyce, D., & Takabe, K. (2019) · Surgery · doi:10.1016/j.surg.2019.09.018 · Cited by 80
Saraiva, D. P., Matias, A. T., Braga, S. A., Jacinto, A., & Cabral, M. G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01543 · Cited by 79
Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
Watase, C., Shiino, S., Shimoi, T., Noguchi, E., Kaneda, T., Yamamoto, Y., Yonemori, K., Takayama, S., & Suto, A. (2021) · Cancers · doi:10.3390/cancers13051078 · Cited by 84
Biomaterial-based platforms for tumour tissue engineering
Curvello, R., Kast, V., Ordóñez‐Morán, P., Mata, Á., & Loessner, D. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00535-3 · Cited by 82
Sun, K., Yu, W., Ji, B., Chen, C., Yang, H., Du, Y., Song, M., Cai, H., Yan, F., & Su, R. J. (2019) · Applied Materials Today · doi:10.1016/j.apmt.2019.100505 · Cited by 78
Ghouse, S. M., Nguyen, H.-M., Bommareddy, P. K., Guz-Montgomery, K., & Saha, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00384 · Cited by 78
Waliany, S., Lee, D. C., Witteles, R. M., Neal, J. W., Nguyen, P. K. P., Davis, M. M., Salem, J., Wu, S. M., Moslehi, J. J., & Zhu, H. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023451 · Cited by 77
Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic
Fraguas‐Sánchez, A. I., Lozza, I., & Torres‐Suárez, A. I. (2022) · Cancers · doi:10.3390/cancers14051198 · Cited by 80
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
Lee, J. V., Housley, F., Yau, C. S. F., Nakagawa, R. M., Winkler, J., Anttila, J. M., Munne, P., Savelius, M., Houlahan, K. E., de Mark, D. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31238-y · Cited by 81
Self-citationT-cell repertoire diversity: friend or foe for protective antitumor response?
Porciello, N., Franzese, O., D’Ambrosio, L., Palermo, B., & Nisticò, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02566-0 · Cited by 88
Chen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 84
Yuan, C., Liu, Z., Yu, Q., Wang, X., Bian, M., Yu, Z., & Yu, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50898-3 · Cited by 78
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
Barchiesi, G., Mazzotta, M., Krasniqi, E., Pizzuti, L., Marinelli, D., Capomolla, E. M., Sergi, D., Amodio, A., Natoli, C., Gamucci, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103528 · Cited by 80
Immune response drives outcomes in prostate cancer: implications for immunotherapy
Meng, J., Zhou, Y., Lu, X., Bian, Z., Chen, Y., Fan, S., Zhou, J., Zhang, L., 郝宗耀, Zhang, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12887 · Cited by 77
An insight into aptamer engineered dendrimer for cancer therapy
Sheikh, A., & Kesharwani, P. (2021) · European Polymer Journal · doi:10.1016/j.eurpolymj.2021.110746 · Cited by 77
Pellegrino, B., Musolino, A., Llop‐Guevara, A., Serra, V., Silva, P. D., Hlavata, Z., Sangiolo, D., Willard-Gallo, K. E., & Solinas, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.010 · Cited by 77
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 79
A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy
Zheng, D., Gao, F., Qian, C., Bao, P., Dong, X., Fan, J., Song, W. L., Zeng, X., Cheng, S., & Zhang, X. (2020) · Nature Communications · doi:10.1038/s41467-020-15927-0 · Cited by 77
Centrosome dysfunction: a link between senescence and tumor immunity
Wu, Q., Li, B., Liu, L., Sun, S., & Sun, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00214-7 · Cited by 78
Understanding PD-L1 Testing in Breast Cancer: A Practical Approach
Erber, R., & Hartmann, A. (2020) · Breast Care · doi:10.1159/000510812 · Cited by 80
Cortés, J., André, F., Gonçalvès, A., Kümmel, S., Mart´n, M., Schmid, P., Schütz, F., Swain, S. M., Easton, V., Pollex, E. K., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0059 · Cited by 75
Self-citationZugazagoitia, J., Liu, Y., Toki, M. I., McGuire, J., Ahmed, F. S., Henick, B. S., Gupta, R., Gettinger, S. N., Herbst, R. S., Schalper, K. A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.014 · Cited by 75
Immune gene expression profiling reveals heterogeneity in luminal breast tumors
Zhu, B., Tse, L. A., Wang, D., Koka, H., Zhang, T., Abubakar, M., Lee, P. M. Y., Wang, F., Wu, Ç., Tsang, K. H., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1218-9 · Cited by 75
The mutational landscape of the SCAN‐B real‐world primary breast cancer transcriptome
Brueffer, C., Gladchuk, S., Winter, C., Vallon‐Christersson, J., Hegardt, C., Häkkinen, J., George, A. M., Chen, Y., Ehinger, A., Larsson, C., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012118 · Cited by 72
Khaddour, K., Johanns, T. M., & Ansstas, G. (2020) · Pharmaceuticals · doi:10.3390/ph13110389 · Cited by 78
CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer
Petruk, N., Tuominen, S., Åkerfelt, M., Mattsson, J., Sandholm, J. A., Nees, M., Yegutkin, G. G., Jukkola‐Vuorinen, A., Tuomela, J. M., & Selander, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-85379-z · Cited by 80
Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes
Osarogiagbon, R. U., Sineshaw, H. M., Unger, J. M., Acuña-Villaorduña, A., & Goel, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_323523 · Cited by 80
Review of immune checkpoint inhibitors in immuno-oncology
Jacob, J. B., Jacob, M. K., & Parajuli, P. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.01.002 · Cited by 80
Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer
Mu, Q., Lin, G., Jeon, M., Wang, H., Chang, F., Revia, R. A., Yu, J. S., & Zhang, M. (2021) · Materials Today · doi:10.1016/j.mattod.2021.08.002 · Cited by 78
Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
Newton, E. E., Mueller, L. E., Treadwell, S. M., Morris, C. A., & Machado, H. L. (2022) · Cancers · doi:10.3390/cancers14030482 · Cited by 83
Wang, B., Sun, T., Zhao, Y., Wang, S., Zhang, J., Wang, Z., Teng, Y.-E., Cai, L., Yan, M., Wang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31704-7 · Cited by 75
Liu, Y., Zhu, X.-Z., Xiao, Y., Wu, S., Zuo, W., Yu, Q., Cao, A., Li, J., Yu, K., Liu, G., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00795-2 · Cited by 75
du Rusquec, P., de Calbiac, O., Robert, M., Campone, M., & Frenel, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s151023 · Cited by 77
Fumet, J.-D., Limagne, E., Thibaudin, M., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12092637 · Cited by 80
Mills, M. N., Figura, N. B., Arrington, J. A., Yu, H.-H. M., Etame, A. B., Vogelbaum, M. A., Soliman, H. H., Czerniecki, B. J., Forsyth, P. A., Han, H. S., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05552-2 · Cited by 75
Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti‐tumor immunity
Sipe, L. M., Chaib, M., Pingili, A. K., Pierre, J. F., & Makowski, L. (2020) · Immunological Reviews · doi:10.1111/imr.12856 · Cited by 75
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression
Pellegrino, B., Hlavata, Z., Migali, C., Silva, P. D., Aiello, M. M., Willard-Gallo, K. E., Musolino, A., & Solinas, C. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00525-7 · Cited by 76
Wu, C., Jarrett, A. M., Zhou, Z., Elshafeey, N. A., Adrada, B. E., Candelaria, R. P., Mohamed, R. M. M., Böge, M., Huo, L., White, J. B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1329 · Cited by 79
Robert, M. E., Rüschoff, J., Jasani, B., Graham, R. P., Badve, S., Rodriguez‐Justo, M., Kodach, L. L., Srivastava, A., Wang, H. L., Tang, L. H., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100154 · Cited by 74
Taylor, B. C., Sun, X., Ericsson, P. I. G., Sanchez, V. M., Sanders, M. E., Wescott, E. C., Opalenik, S. R., Hanna, A., Chou, S.-T., Kaer, L. V., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0519 · Cited by 77
Immunotherapy in breast cancer
Bayraktar, S., Batoo, S. A., Okuno, S. H., & Glück, S. (2019) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_2_19 · Cited by 77
Anderson, R., Theron, A. J., & Rapoport, B. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02254 · Cited by 73
Saleiro, D., & Platanias, L. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101299 · Cited by 76
Montagna, G., Gupta, H. V., Hannum, M., Tan, K. S., Lee, J., Scarpa, J. R., Plitas, G., Irie, T., McCormick, P. J., Fischer, G. W., et al. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.10.021 · Cited by 72
DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Kurani, H., Razavipour, S. F., Harikumar, K. B., Dunworth, M., Ewald, A. J., Nasir, A., Pearson, G. W., Booven, D. V., Zhou, Z., Azzam, D. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1299 · Cited by 73
Breast cancer brain metastasis: Current evidence and future directions
Sun, H., Xu, J., Dai, S., Ma, Y., & Sun, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5021 · Cited by 77
Zhao, S., Chen, D.-P., Fu, T., Yang, J., Ma, D., Zhu, X.-Z., Wang, X.-X., Jiao, Y., Jin, X., Xiao, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42504-y · Cited by 79
Metastasis as a systemic disease: molecular insights and clinical implications
Alečković, M., McAllister, S. S., & Polyák, K. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.06.002 · Cited by 73
Update on the Management of Breast Cancer during Pregnancy
Poggio, F. B., Tagliamento, M., Pirrone, C., Soldato, D., Conte, B., Molinelli, C., Cosso, M., Fregatti, P., Mastro, L. D., & Lambertini, M. (2020) · Cancers · doi:10.3390/cancers12123616 · Cited by 74
Immunotherapy in Triple-Negative Breast Cancer
Emens, L. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000497 · Cited by 71
Self-citationMimura, K., Kua, L., Xiao, J.-F., Asuncion, B. R., Nakayama, Y., Syn, N. L. X., Fazreen, Z., Soong, R. C. T., Kono, K., & Yong, W. P. (2021) · Gastric Cancer · doi:10.1007/s10120-020-01151-8 · Cited by 75
Gyawali, B., de Vries, E. G. E., Dafni, U. G., Amaral, T. M. S., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez‐Roca, C., Kiesewetter, B., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100117 · Cited by 73
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 77
Moy, B., Rumble, R. B., Come, S. E., Davidson, N. E., Leo, A. D., Gralow, J. R., Hortobágyi, G. N., Yee, D., Smith, I. E., Chávez‐MacGregor, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01374 · Cited by 72
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 75
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Arora, S., Narayan, P., Osgood, C. L., Wedam, S. B., Prowell, T. M., Gao, J. J., Shah, M., Krol, D., Wahby, S., Royce, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2600 · Cited by 76
Najjar, S. N., & Allison, K. H. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03267-x · Cited by 75
Sanchez, K. G., Kim, I., Chun, B., Pucilowska, J., Redmond, W. L., Urba, W. J., Martel, M., Wu, Y., Campbell, M. B., Sun, Z., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-020-01378-4 · Cited by 72
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials
Zhu, M. M. T., Shenasa, E., & Nielsen, T. O. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102115 · Cited by 75
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice
Claessens, A. K. M., Ibragimova, K. I. E., Geurts, S. M. E., Bos, M. E. M. M., Erdkamp, F., & Tjan‐Heijnen, V. C. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102988 · Cited by 75
Lyu, L., Yao, J., Wang, M., Zheng, Y., Xu, P., Wang, S., Zhang, D., Deng, Y., Wu, Y., Yang, S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01245 · Cited by 71
Autio, K. A., Klebanoff, C. A., Schaer, D., Kauh, J. S. W., Slovin, S. F., Adamow, M. J., Blinder, V. S., Brahmachary, M., Carlsen, M., Comen, E. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0855 · Cited by 72
Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls
Cimino‐Mathews, A. (2020) · Modern Pathology · doi:10.1038/s41379-020-00697-3 · Cited by 73
Sampsell, K., Hao, D., & Reimer, R. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239239 · Cited by 74
O’Melia, M. J., Manspeaker, M. P., & Thomas, S. N. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02792-5 · Cited by 69
Foldi, J., Silber, A. L. M., Reisenbichler, E., Singh, K., Fischbach, N. A., Persico, J., Adelson, K. B., Katoch, A., Horowitz, N. R., Lannin, D. R., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00219-7 · Cited by 71
Li, T., Tao, Z., Zhu, Y., Liu, X., Wang, L., Du, Y., Cao, J., Wang, B., Zhang, J., & Hu, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03963-7 · Cited by 71
Wei, D., Wang, H., Zeng, Q., Wang, W., Hao, B., Feng, X., Wang, P., Song, N., Kan, W., Huang, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01350 · Cited by 72
Update on prognostic and predictive biomarkers of breast cancer
Hou, Y., Peng, Y. S., & Li, Z. (2022) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2022.06.015 · Cited by 72
Kim, C. M., Lee, J. B., Shin, S. J., Ahn, J. B., Lee, M., & Kim, H. S. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100577 · Cited by 77
“100577).(3,25-53) Among the 30 trials included in the meta-analysis, 16 trials used PD-1 inhibitors (8 used nivolumab and 8 used pembrolizumab), 6 used PD-L1 inhibitors [avelumab (n 1⁄4 2), atezolizumab (n 1⁄4 3), durvalumab (n 1⁄4 1)], and 6 used antiCTLA-4 [tremelimumab (n 1⁄4 2), ipilimumab (n 1⁄4 4), and combinati…”
BackgroundYang, M., Qin, C., Tao, L., Cheng, G., Li, J., Lv, F., Yang, N., Xing, Z., Chu, X., Han, X., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122253 · Cited by 75
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 71
BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer
Jing, X., Shao, S. H., Zhang, Y., Luo, A., Zhao, L., Zhang, L., Gu, S., & Zhao, X. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112034 · Cited by 72
Takahashi, H., Kawaguchi, T., Yan, L., Peng, X., Qi, Q., Morris, L. G. T., Chan, T. A.-T., Tsung, A., Otsuji, E., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12051221 · Cited by 70
Gut bacterial microbiome composition and statin intake—A systematic review
Dias, A. M., Cordeiro, G., Estevinho, M. M., Veiga, R., Figueira, L., Reina‐Couto, M., & Magro, F. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.601 · Cited by 71
Telli, M. L., Nagata, H., Wapnir, I., Acharya, C. R., Zablotsky, K., Fox, B. A., Bifulco, C. B., Jensen, S. M., Ballesteros‐Merino, C., Le, M. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3944 · Cited by 72
Zhou, W., Yu, M., Mao, X., Pan, H., Tang, X., Ji, W., Che, N., Xie, H., Ling, L., Zhao, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202200033 · Cited by 70
Bonsu, J. M., Guha, A., Charles, L., Yildiz, V. O., Wei, L., Baker, B., Brammer, J. E., Awan, F. T., Lustberg, M. B., Reinbolt, R. E., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.059 · Cited by 70
Scioli, M. G., Storti, G., D’Amico, F., Gentile, P., Fabbri, G., Cervelli, V., & Orlandi, A. (2019) · Cancers · doi:10.3390/cancers11071021 · Cited by 71
Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
Saleh, R., Peinado, P., Fuentes‐Antrás, J., Pérez‐Segura, P., Pandiella, A., Amir, E., & Ocaña, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01040 · Cited by 70
circGNB1 Facilitates Triple-Negative Breast Cancer Progression by Regulating miR-141-5p-IGF1R Axis
Liu, P., Zou, Y., Li, X., Yang, A., Ye, F., Zhang, J., Wei, W., & Kong, Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00193 · Cited by 70
Serpico, A. F., Visconti, R., & Grieco, D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2567-0 · Cited by 70
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Magnes, T., Wagner, S. M., Kiem, D., Weiß, L., Rinnerthaler, G., Greil, R., & Melchardt, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094981 · Cited by 74
The Breast Tumor Microenvironment: A Key Player in Metastatic Spread
Terceiro, L. E. L., Edechi, C. A., Ikeogu, N. M., Nickel, B. E., Hombach‐Klonisch, S., Sharif, T., Leygue, E., & Myal, Y. (2021) · Cancers · doi:10.3390/cancers13194798 · Cited by 69
Metadata
- Authors
- Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., Henschel, V., Molinero, L., Chui, S. Y., Funke, R., Husain, A., Winer, E. P., Loi, S., & Emens, L. A.
- Affiliations
- Queen Mary University of London (GB)
- From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) — both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul,...
- Seoul National University (KR)
- F. Hoffmann-La Roche AG (CH)
- The University of Melbourne (AU)
- Johns Hopkins University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2108-2121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2897422388
- Cited by
- 4,350
- References
- 32
- Citations by year
- 2026: 310 · 2025: 409 · 2024: 453 · 2023: 562 · 2022: 648 · 2021: 825 · 2020: 723 · 2019: 397 · 2018: 17
- FWCI
- 148.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche/Genentech
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- atezolizumab, nab-paclitaxel, triple-negative breast cancer, metastatic breast cancer, PD-L1 expression, immune checkpoint inhibitors, combination chemotherapy, progression-free survival, overall survival, liver metastasis, immune-related adverse events, PD-1/PD-L1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Albumins, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Survival Analysis, Paclitaxel, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
